Janssen, as part of its commitment to Global Public Health, cultivates and helps implement innovative pricing and results-based financing models that improve access to our medicines for patients in resource-limited and emerging markets. We are also creating sustainable, long-term solutions based on country ownership and accountability for both health services and outcomes.
Janssen unifies our commitment to research, develop and deliver transformational medicines to address the world’s greatest unmet public health needs by:
- Ensuring we have research efforts focused on neglected diseases and medical needs that disproportionally impact public health settings; and
- Creating and facilitating sustainable and affordable access to our medicines in developing markets.
We work to identify and develop vaccines, diagnostics, medicines and services to address unmet medical needs in areas such as HIV, multi-drug resistant tuberculosis (MDR-TB), intestinal worms and neglected tropical diseases (NTDs).
Access to HIV Treatment
With over 35 million people living with HIV/AIDS today and only 11.7 million people in low- and middle-income countries receiving HIV medicines, expanding access to HIV treatment is a top global public health priority in resource-limited settings.
Our HIV medicines access program has been working to ensure that people in resource-limited countries with HIV/AIDS have effective and sustainable access to HIV medicines and know how to use them safely and appropriately. Learn more about our HIV Medicines Access & Partnerships Program.
Our HIV Medicines Access & Partnerships Program addresses the unique challenges of HIV medicine access in resource-limited settings:
- Availability: Registration efforts and product introduction prioritized by disease burden
- Affordability: Reduced access pricing and proactive intellectual property management to facilitate generic versions of Janssen’s HIV medicines within the territory
- Appropriate Use: Support for joint medical education trainings and clinical studies in resource-limited settings
- Adoption: Inclusion in World Health Organization, regional and national guidelines, and support of pre- and post-approval procurement
As a key element of our work in global public health, our global HIV Medicines Access & Partnerships Program is working to fulfill our responsibility to people living with HIV/AIDS. Through our comprehensive HIV drug access framework, we work to fulfill our responsibility to provide access to our medicines, specifically in least-developed countries and lower middle-income countries (LDCs and LMICs).
Access to MDR-TB Treatment
Janssen is also committed to addressing the global health crisis of tuberculosis (TB). Through public-private partnerships in research and development, differentiated pricing and collaborations around responsible use and distribution, we are working to ensure that treatment is accessible for vulnerable populations in countries where it is approved. Worldwide registration efforts are currently underway, prioritizing countries with the greatest disease burden and public health need.
To this end, in 2009, Janssen entered into an agreement with the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership, to collaborate in sharing expertise and resources. Continued partnership with organizations such as the TB Alliance has included a royalty-free license to promote broader access to tuberculosis therapies.
Our novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), aims to enhance access to more than 130 low- and middle-income countries.
Access to NTD Treatment
We are developing new treatments for intestinal worms in younger children. As part of our London Declaration pledge, we are aiming to donate up to 200 million doses per year to reach at least 30 countries through 2020.
Ultimately, Janssen strives to reimagine how our business can deliver on the promise of our medicines across the world. We do this because we want to make a meaningful difference in global public health.